SASKATOON, Saskatchewan, May 01, 2025 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce that, further to its news release dated April 3, 2025, it has completed the acquisition of all issued and outstanding shares of a pre-1954 charter company (the “Charter Company”) in Ontario, Canada (the “Acquisition”). The Acquisition of the Charter Company is an arm’s length transaction and no finder’s fees were paid in respect of the Acquisition. The Acquisit ...

Summary of Pacira BioSciences Inc (PCRX) Update / Briefing April 27, 2025 Company Overview - **Company**: Pacira BioSciences Inc (PCRX) - **Focus**: Development of innovative therapies for pain management and degenerative diseases, specifically targeting osteoarthritis Key Points - **Commitment to Change**: The company emphasizes its dedication to creating lasting improvements for patients suffering from pain and degenerative diseases like osteoarthritis [1] - **Clinical Development Plan**: Introduction of PCRX201, an innovative gene therapy aimed at addressing both the underlying causes and symptoms of knee osteoarthritis [1] Additional Important Content - **Target Patient Population**: The focus on osteoarthritis indicates a strategic alignment with a significant patient demographic that experiences chronic pain [1]

PCRX-201 | Innovative gene therapy targeting underlying cause of osteoarthritis Jonathan Slonin, Chief Medical Officer April 2025 Forward-looking statements and where to find additional information Patients suffering from knee OA say it impacts5 Any statements in this presentation about Pacira's future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words "believes," "anticipates," "plans," "estimates," "expects," "intends," "may," "will," "would," "could ...

Core Insights - Pacira BioSciences, Inc. is presenting new 104-week data for its gene therapy candidate PCRX-201 at the OARSI World Congress, highlighting its commitment to innovative, non-opioid pain therapies [1][4]. Group 1: Product Information - PCRX-201 (enekinragene inzadenovec) is based on a proprietary high-capacity adenovirus vector platform and targets chronic inflammatory processes in knee osteoarthritis, affecting over 14 million individuals in the U.S. [3] - The therapy has shown sustained improvements in knee pain, stiffness, and function for up to two years post-administration, with a favorable safety profile [4]. - PCRX-201 has received RMAT designation from the FDA and ATMP designation from the EMA, marking it as the first gene therapy to achieve such regulatory recognition in knee osteoarthritis [4]. Group 2: Clinical Development - Following promising Phase 1 results, a Phase 2 study (ASCEND study) is currently underway for PCRX-201 to further evaluate its efficacy in treating knee osteoarthritis [5]. Group 3: Company Overview - Pacira specializes in non-opioid pain therapies and has three commercial-stage products: EXPAREL®, ZILRETTA®, and iovera® [6]. - The company is advancing the development of PCRX-201 as a novel treatment option for prevalent diseases like osteoarthritis [6].

Group 1 - PharmaCorp Rx Inc. has filed its audited financial statements and associated MD&A for the year ended December 31, 2024, on SEDAR+ [1] - The company operates three PharmaChoice bannered pharmacies in Canada and plans to acquire more as they become available [2] - PharmaCorp intends to acquire independently owned non-PharmaChoice Canada bannered pharmacies and operate them under the PharmaChoice Canada banner [2] Group 2 - PharmaCorp shares are traded on the TSX Venture Exchange under the symbol PCRX [2]

Core Insights - Pacira (PCRX) has consistently surpassed earnings estimates, averaging a 7.77% beat over the last two quarters [1] - In the last reported quarter, Pacira achieved earnings of $0.91 per share, exceeding the Zacks Consensus Estimate of $0.86 per share by 5.81% [2] - The previous quarter also saw Pacira outperforming expectations, with actual earnings of $0.79 per share against an estimate of $0.72 per share, resulting in a surprise of 9.72% [2] Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for Pacira, with a positive Zacks Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [4] - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [5] - Pacira currently has an Earnings ESP of +12.06%, suggesting analysts are optimistic about the company's earnings prospects [7] Importance of Earnings ESP - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [6] - A positive Earnings ESP combined with a Zacks Rank 3 indicates a potential earnings beat, while a negative value reduces predictive power but does not guarantee a miss [7] - It is crucial to check a company's Earnings ESP before quarterly releases to enhance the likelihood of successful investment decisions [8]

Core Viewpoint - DOMA Perpetual believes that Pacira BioSciences' stock is undervalued, presenting an opportunity for the company to execute its largest buyback in history [1][4]. Group 1: Capital Allocation and Shareholder Value - DOMA Perpetual views the new capital allocation announcement as a strong commitment from Pacira's Board to enhance shareholder value [2]. - The combination of a $300 million share repurchase program and a focus on increasing pre-tax net income margins is expected to strengthen shareholder returns [3]. - The management is now tasked with effectively executing these initiatives to realize their potential [3]. Group 2: Growth and Financial Position - DOMA Perpetual is encouraged by Pacira's steps towards long-term value creation, indicating a period of rapid growth for the company [4]. - The new capital allocation priorities reflect Pacira's considerable momentum in scaling earnings and free cash flow, allowing for meaningful capital returns to shareholders while still investing in growth [4]. - The stock is considered undervalued relative to its historical average and the anticipated multi-year growth cycle ahead [4].

Core Viewpoint - Pacira BioSciences, Inc. is committed to enhancing shareholder value through strategic actions aimed at optimizing operational performance and creating sustainable, long-term value for shareholders [1][3] Group 1: Strategic Initiatives - The company has made significant progress in advancing its 5x30 strategy to transition into an innovative biopharmaceutical organization and aims to become a leader in musculoskeletal pain and related areas by 2030 [2] - The Board of Directors has authorized a share repurchase program of up to $300 million, reinforcing confidence in the company's growth strategy and commitment to shareholder value [5] - The company is focused on enhancing operational efficiency and aims to improve gross margins by 5 percentage points over 2024 [5] Group 2: Product Portfolio - Pacira offers three commercial-stage non-opioid treatments: EXPAREL®, ZILRETTA®, and iovera®º, which are designed to manage pain without opioids [4] - The company is advancing the development of PCRX-201, a novel locally administered gene therapy aimed at treating prevalent diseases like osteoarthritis [4] Group 3: Future Outlook - Pacira plans to treat more than 3 million patients annually and aims for a double-digit compounded annual growth rate for revenue [5] - The company is expanding its clinical pipeline with five novel programs in development and establishing five new partnerships, including pipeline and commercial agreements [5]

Core Insights - Pacira BioSciences, Inc. (NASDAQ: PCRX) is a specialty pharmaceutical company focused on non-opioid pain management therapies, with key products including Exparel, Zilretta, and iovera [1] Group 1 - The NOPAIN Act is expected to provide a favorable secular tailwind for Pacira BioSciences, enhancing the market for non-opioid pain management solutions [1]

Core Viewpoint - Pacira BioSciences has settled litigation with Fresenius Kabi and others regarding patents for EXPAREL, allowing Fresenius to sell a volume-limited amount of generic bupivacaine liposome injectable suspension starting in early 2030, with unlimited sales permitted from 2039 [1][3][4]. Group 1: Settlement Details - The settlement includes Consent Judgments that prevent Fresenius from marketing the generic product before the expiration of the relevant patents, except as specified in the settlement [2]. - Fresenius will receive a license to manufacture and sell a limited volume of the generic product starting in early 2030, with the last of Pacira's patents expiring on July 2, 2044 [3]. - The volume-limited sales will start at a high-single-digit percentage of total U.S. market volumes, increasing to the low thirties by 2033, and reaching a maximum in the high thirties for the final three years of the agreement [4]. Group 2: Company Strategy and Products - Pacira emphasizes confidence in its intellectual property portfolio and aims to focus on advancing its 5x30 strategy to enhance its leadership in musculoskeletal pain management [5]. - The company offers three commercial-stage non-opioid treatments: EXPAREL, ZILRETTA, and iovera, and is developing PCRX-201, a gene therapy for osteoarthritis [6].